| Drug Name: | Furosemide (54-31-9) |
|---|---|
| PubChem ID: | 3440 |
| SMILES: | C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl |
| InchiKey: | ZZUFCTLCJUWOSV-UHFFFAOYSA-N |
| Therapeutic Category: | Diuretics, Membrane Transport Modulators, Natriuretic Agents, Sodium Potassium Chloride Symporter Inhibitors |
| Molecular Weight (dalton) | : | 330.749 |
| LogP | : | 1.8907 |
| Ring Count | : | 2 |
| Hydrogen Bond Acceptor Count | : | 5 |
| Hydrogen Bond Donor Count | : | 3 |
| Total Polar Surface Area | : | 122.63 |
This panel provides information on interacting drugs and their ADRs along with references
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Bone Demineralization | Parathyroid hormone (Q03431) | Four preterm infants receiving long-term furosemide therapy were examined for hypercalciuria@ hyperparathyroidism@ renal calcification@ and bone demineralization Three of them had high serum concentrations of parathyroid hormone [ ADR Type 2 ] | Secondary hyperparathyroidism and bone disease in infants receiving long-term furosemide therapy |
| Hypercalciuria | Parathyroid hormone (Q03431) | Four preterm infants receiving long-term furosemide therapy were examined for hypercalciuria@ hyperparathyroidism@ renal calcification@ and bone demineralization Three of them had high serum concentrations of parathyroid hormone [ ADR Type 2 ] | Secondary hyperparathyroidism and bone disease in infants receiving long-term furosemide therapy |
| Hyperparathyroidism | Parathyroid hormone (Q03431) | Four preterm infants receiving long-term furosemide therapy were examined for hypercalciuria@ hyperparathyroidism@ renal calcification@ and bone demineralization Three of them had high serum concentrations of parathyroid hormone [ ADR Type 2 ] | Secondary hyperparathyroidism and bone disease in infants receiving long-term furosemide therapy |
| Renal Calcification | Parathyroid hormone (Q03431) | Four preterm infants receiving long-term furosemide therapy were examined for hypercalciuria@ hyperparathyroidism@ renal calcification@ and bone demineralization Three of them had high serum concentrations of parathyroid hormone [ ADR Type 2 ] | Secondary hyperparathyroidism and bone disease in infants receiving long-term furosemide therapy |
| Renal Failure | Lipoprotein lipase precursor (P06858) | The activity of postherapin lipoprotein lipase was significantly lower in the patients than in the controls@which leads to renal failure [ ADR Type 2 ] | Effect of furosemide on the lipid abnormalities in chronic renal failure |
| Renal Failure | Very low density lipoprotein (P98155) | The concentrations of serum total@ VLDL and LDL triglycerides were significantly higher@which leads to renal failure [ ADR Type 2 ] | Effect of furosemide on the lipid abnormalities in chronic renal failure |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category